Debate-a bridge too far: Nonalcoholic fatty liver disease will not exhaust the donor pool

Liver Transplantation

Volumn 20, Issue S2, 2014, Pages S38-S41

  O'Leary, Jacqueline G ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC KIDNEY DISEASE; DONOR; EARLY DIAGNOSIS; EARLY INTERVENTION; HUMAN; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MORTALITY; NONALCOHOLIC FATTY LIVER; POSTOPERATIVE PERIOD; PREVALENCE; SURVIVAL; SYSTEMIC DISEASE; TREATMENT OUTCOME; ADVERSE EFFECTS; GRAFT SURVIVAL; HEALTH CARE DELIVERY; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POSTOPERATIVE COMPLICATION; PROCEDURES; RISK ASSESSMENT; RISK FACTOR; SUPPLY AND DISTRIBUTION; TIME FACTOR;

GRAFT SURVIVAL; HEALTH SERVICES ACCESSIBILITY; HUMANS; LIVER TRANSPLANTATION; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POSTOPERATIVE COMPLICATIONS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME;

EID: 84911421221     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23973     Document Type: Article

References (15)

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012;55: 2005-2023.
2. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-344.
3. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873.
4. Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013;145:782-789.
5. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465.
6. O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011;9:700-704.
7. Trotter J, Arenas JD, Bynon JS, Duffy J, Elbeshbeshy HA, Foster PF, et al. A preliminary analysis of liver allocation based on the "Share 35" policy in UNOS region 4 [Abstract]. Hepatology 2014 (suppl); in press.
8. Asrani SK. Liver transplantation for nonalcoholic steato-hepatitis. Clin Gastroenterol Hepatol 2014;12:403-404.
9. Fussner LA, Charlton MR, Heimbach JK, Fan C, Dierkhising R, Coss E, Watt KD. The impact of gender and NASH on chronic kidney disease before and after liver transplantation. Liver Int 2014;34:1259-1266.
10. Singal AK, Salameh H, Kuo YF, Wiesner RH. Evolving frequency and outcomes of simultaneous liver kidney transplants based on liver disease etiology. Transplantation 2014;98:216-221.
11. Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl 2010;16:431-439.
12. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009;9:782-793.
13. VanWagner LB, Bhave M, Te HS, Feinglass J, Alvarez L, Rinella ME. Patients transplanted for non-alcoholic stea-tohepatitis are at increased risk for postoperative cardiovascular events. Hepatology 2012;56:1741-1750.
14. Heimbach JK, Watt KDS, Poterucha JJ, Francisco Ziller N, Cecco SD, Charlton MR, Hay JE, Wiesner RH, Sanchez W, Rosen CB, Swain JM. Combined liver transplantation and gastric sleeve resection for patients with medically complicated obesity and end-stage liver disease. American Journal of Transplantation 2013;13:363-368.
15. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease-the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014;39:254-269.